Balaxi Pharmaceuticals Limited
NSE: BALAXI
Prev Close
66.1
Open Price
67.1
Volume
140,024
Today Low / High
63.85 / 67.19
52 WK Low / High
50.42 / 151.45
Range
61 - 68
Currently, the stock is trading on the National Stock Exchange (NSE). The stock price stands at 64.61, with a change of -1.49 (-2.25416%). The expected target range on the NSE is between 61 - 68. The stock is experiencing a downward trend on the NSE. Investors should be cautious as the price is currently declining.
Balaxi Pharmaceuticals Limited Graph
Balaxi Pharmaceuticals Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Balaxi Pharmaceuticals Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 64.61, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 64.61 | 65.26 | 58.73 - 71.78 |
| 65.90 | 52.72 - 79.08 | ||
| 66.55 | 46.58 - 86.51 | ||
| Bearish Scenario | 64.61 | 63.96 | 57.57 - 70.36 |
| 63.32 | 50.65 - 75.98 | ||
| 62.67 | 43.87 - 81.47 |
Overview of Balaxi Pharmaceuticals Limited
ISIN
INE618N01014
Industry
Medical - Equipment & Services
Vol.Avg
317,636
Market Cap
722,672,929
Last Dividend
0
Official Website
IPO Date
2015-12-02
DCF Diff
N/A
DCF
0
Financial Ratios Every Investor Needs
Stock Dividend of BALAXI
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2022-07-01 | July 01, 22 | 0.5 | 0.5 | 2022-07-04 | 2022-08-10 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 241.29 Cr | 128.68 Cr | 112.61 Cr | 0.4667 | 0.00 Cr | 27.79 Cr | 46.73 Cr | -2.39 Cr | -0.46 | 45.66 Cr | -0.0099 |
| 2023-03-31 | 336.43 Cr | 202.42 Cr | 134.02 Cr | 0.3983 | 0.00 Cr | 48.53 Cr | 57.42 Cr | 45.96 Cr | 9.16 | 59.17 Cr | 0.1366 |
| 2022-03-31 | 279.39 Cr | 195.60 Cr | 83.79 Cr | 0.2999 | 0.00 Cr | 13.14 Cr | 54.66 Cr | 47.66 Cr | 9.53 | 55.18 Cr | 0.1706 |
| 2021-03-31 | 231.33 Cr | 172.15 Cr | 59.19 Cr | 0.2558 | 0.00 Cr | 0.58 Cr | 44.38 Cr | 38.14 Cr | 7.63 | 44.68 Cr | 0.1649 |
| 2020-03-31 | 45.63 Cr | 33.58 Cr | 12.06 Cr | 0.2642 | 0.00 Cr | 0.12 Cr | 8.23 Cr | 6.10 Cr | 1.62 | 8.24 Cr | 0.1338 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 62.29 Cr | 258.34 Cr | 56.98 Cr | 201.3639 Cr | 19.40 Cr | -42.89 Cr | 82.17 Cr | 16.31 Cr | 2.88 Cr | 0.00 Cr | -258.34 Cr | 54.1973 Cr |
| 2023-03-31 | 28.22 Cr | 239.67 Cr | 56.79 Cr | 182.8798 Cr | 13.31 Cr | -14.91 Cr | 105.02 Cr | 19.02 Cr | 5.06 Cr | 56.79 Cr | -239.67 Cr | 53.1333 Cr |
| 2022-03-31 | 7.19 Cr | 176.47 Cr | 63.31 Cr | 113.1641 Cr | 3.64 Cr | -3.55 Cr | 98.70 Cr | 5.20 Cr | 0.00 Cr | -2.56 Cr | 4.47 Cr | 63.2676 Cr |
| 2021-03-31 | 1.67 Cr | 99.68 Cr | 34.70 Cr | 64.9798 Cr | 3.66 Cr | 1.99 Cr | 13.62 Cr | 1.17 Cr | 8.85 Cr | 34.70 Cr | 3.42 Cr | 34.6927 Cr |
| 2020-03-31 | 4.00 Cr | 35.97 Cr | 8.23 Cr | 27.7460 Cr | 0.92 Cr | -3.08 Cr | 0.83 Cr | 0.19 Cr | 0.00 Cr | 8.23 Cr | 0.00 Cr | 8.2218 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 3.3403 Cr | -1.0463 Cr | 30.2539 Cr | 3.2967 Cr | 34.0738 Cr | 62.2906 Cr | -0.6926 Cr | 2.0153 Cr | 6.0402 Cr | 0.0000 Cr | 22.8553 Cr |
| 2023-03-31 | 6.0753 Cr | -10.5654 Cr | 25.5126 Cr | -8.9046 Cr | 21.0225 Cr | 28.2122 Cr | -14.9799 Cr | 56.9223 Cr | 7.9827 Cr | -0.4984 Cr | -6.3197 Cr |
| 2022-03-31 | 34.1445 Cr | -28.4483 Cr | -0.1628 Cr | 6.8002 Cr | 5.5333 Cr | 7.1898 Cr | -27.3443 Cr | 54.5223 Cr | -0.0211 Cr | 0.0000 Cr | -85.0857 Cr |
| 2021-03-31 | 0.0032 Cr | -5.9728 Cr | 3.6461 Cr | -2.5532 Cr | -2.3235 Cr | 1.6565 Cr | -2.5564 Cr | 44.3293 Cr | 3.6592 Cr | 0.0000 Cr | -12.7858 Cr |
| 2020-03-31 | -14.0615 Cr | -0.1827 Cr | 18.0960 Cr | -14.2442 Cr | 3.8772 Cr | 3.9800 Cr | -0.1827 Cr | 8.8737 Cr | 0.0000 Cr | 0.0000 Cr | -0.8321 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 73.29 Cr | 43.84 Cr | 29.45 Cr | 0.4019 | 3.51 Cr | 5.36 Cr | 0.97 | 7.93 Cr | 0.0732 |
| 2024-09-30 | 73.27 Cr | 44.17 Cr | 29.10 Cr | 0.3972 | 5.56 Cr | 4.59 Cr | 0.83 | 6.03 Cr | 0.0626 |
| 2024-06-30 | 63.77 Cr | 39.00 Cr | 24.77 Cr | 0.3885 | 7.37 Cr | 6.48 Cr | 1.17 | 7.87 Cr | 0.1016 |
| 2024-03-31 | 58.05 Cr | 30.16 Cr | 27.89 Cr | 0.4804 | 10.40 Cr | 10.93 Cr | 2.08 | 11.08 Cr | 0.1884 |
| 2023-12-31 | 60.79 Cr | 30.36 Cr | 30.42 Cr | 0.5005 | 13.05 Cr | 13.59 Cr | 2.66 | 13.53 Cr | 0.2236 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 60.87 Cr | 0.00 Cr | 60.87 Cr | 81.26 Cr | 0.00 Cr | 239.22 Cr | 16.95 Cr | 287.97 Cr | 72.10 Cr |
| 2024-06-30 | -62.57 Cr | 125.14 Cr | 62.57 Cr | 0.00 Cr | 0.00 Cr | 62.57 Cr | 0.00 Cr | 0.00 Cr | -201.36 Cr |
| 2024-03-31 | 62.29 Cr | 0.28 Cr | 62.29 Cr | 57.13 Cr | 82.17 Cr | 210.17 Cr | 14.78 Cr | 258.34 Cr | 56.98 Cr |
| 2023-12-31 | -28.14 Cr | 56.29 Cr | 28.14 Cr | 0.00 Cr | 0.00 Cr | 28.14 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 28.14 Cr | 0.00 Cr | 28.14 Cr | 44.46 Cr | 85.22 Cr | 163.40 Cr | 17.75 Cr | 214.47 Cr | 59.00 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | 6.48 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 10.93 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 13.59 Cr | 0.96 Cr | 0.00 Cr | 0.00 Cr | 0.96 Cr | 0.96 Cr | 0.00 Cr | 0.00 Cr | 0.96 Cr |
| 2023-09-30 | 14.43 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-06-30 | -41.34 Cr | 0.57 Cr | 0.00 Cr | 0.00 Cr | 0.57 Cr | 28.79 Cr | 28.22 Cr | 0.00 Cr | 0.57 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2024-05-30 | May 30, 24 | 5:1 |
Similar Stocks: Medical - Equipment & Services
No stocks found in this industry.
Key Executives
No executive data available.
FAQs about Balaxi Pharmaceuticals Limited
The CEO is Ashish Maheshwari.
The current price is ₹64.61.
The range is ₹50.42-151.45.
The market capitalization is ₹72.27 crores.
The P/E ratio is 13.05.
The company operates in the Healthcare sector.
Overview of Balaxi Pharmaceuticals Limited (ISIN: INE618N01014) is a leading Medical - Equipment & Services in India. With a market capitalization of ₹72.27 crores and an average daily volume of 317,636 shares, it operates in the Medical - Equipment & Services. The company last declared a dividend of ₹0.